LY3039478

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    LY3039478 is a novel and potent Notch inhibitor with IC50 of 0.41 nM.
    The novel and unique Notch Inhibitor, LY3039478, has progressed into clinical development by Lilly co. ltd. LY3039478 displays the best overall profile and is unique within the SAR investigated. LY3039478 Displays Interesting Atropisomer Phenomena. The average LY3039478 major/minor rotational isomer ratio ranged between 14 and 28 in plasma. The crystalline monohydrate form of LY3039478 consists of a single rotational isomer and is chemically and physically stable for at least 14 days under accelerated stability test conditions.
- Properties
  - Alternative Name
    
    4,4,4-trifluoro-N-[(2S)-1-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide
    
    CAS Number
    
    1421438-81-4
    
    Molecular Formula
    
    C22H23F3N4O4
    
    Molecular Weight
    
    464.44
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    ≥23.2 mg/mL in DMSO; insoluble in H2O; ≥89.4 mg/mL in EtOH with ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Servián-Morilla E, Takeuchi H, et al. "A POGLUT1 mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss." EMBO Mol Med. 2016 Nov 2;8(11):1289-1309. PMID:27807076

LY3039478

Background

We Also Recommend

Telaprevir (VX-950)

VX-222 (VCH-222, Lomibuvir)